Asin KE - Search Results

1

Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data.

Sanchez C, Asin KE, Artigas F. Sanchez C, et al. Among authors: asin ke. Pharmacol Ther. 2015 Jan;145:43-57. doi: 10.1016/j.pharmthera.2014.07.001. Epub 2014 Jul 9. Pharmacol Ther. 2015. PMID: 25016186 Free article. Review.

2

New applications of disease genetics and pharmacogenetics to drug development.

Roses AD, Saunders AM, Lutz MW, Zhang N, Hariri AR, Asin KE, Crenshaw DG, Budur K, Burns DK, Brannan SK. Roses AD, et al. Among authors: asin ke. Curr Opin Pharmacol. 2014 Feb;14:81-9. doi: 10.1016/j.coph.2013.12.002. Epub 2014 Jan 3. Curr Opin Pharmacol. 2014. PMID: 24565016 Free article. Review.

3

Translational Development Strategies for TAK-063, a Phosphodiesterase 10A Inhibitor.

Macek TA, Suzuki K, Asin K, Kimura H. Macek TA, et al. Int J Neuropsychopharmacol. 2020 Nov 26;23(8):524-532. doi: 10.1093/ijnp/pyaa042. Int J Neuropsychopharmacol. 2020. PMID: 32598478 Free PMC article.

4

Effects of low doses of pioglitazone on resting-state functional connectivity in conscious rat brain.

Crenshaw DG, Asin K, Gottschalk WK, Liang Z, Zhang N, Roses AD. Crenshaw DG, et al. PLoS One. 2015 Feb 11;10(2):e0117973. doi: 10.1371/journal.pone.0117973. eCollection 2015. PLoS One. 2015. PMID: 25671601 Free PMC article.

5

ABT-431: the diacetyl prodrug of A-86929, a potent and selective dopamine D1 receptor agonist: in vitro characterization and effects in animal models of Parkinson's disease.

Shiosaki K, Jenner P, Asin KE, Britton DR, Lin CW, Michaelides M, Smith L, Bianchi B, Didomenico S, Hodges L, Hong Y, Mahan L, Mikusa J, Miller T, Nikkel A, Stashko M, Witte D, Williams M. Shiosaki K, et al. Among authors: asin ke. J Pharmacol Exp Ther. 1996 Jan;276(1):150-60. J Pharmacol Exp Ther. 1996. PMID: 8558425

6

The selective dopamine D1 receptor agonist A-86929 maintains efficacy with repeated treatment in rodent and primate models of Parkinson's disease.

Asin KE, Domino EF, Nikkel A, Shiosaki K. Asin KE, et al. J Pharmacol Exp Ther. 1997 Apr;281(1):454-9. J Pharmacol Exp Ther. 1997. PMID: 9103530

7

Differential effects of CCK-JMV-180 on food intake in rats and mice.

Asin KE, Bednarz L. Asin KE, et al. Pharmacol Biochem Behav. 1992 Jun;42(2):291-5. doi: 10.1016/0091-3057(92)90529-o. Pharmacol Biochem Behav. 1992. PMID: 1631182

8

Persistent activation of the dopamine D1 receptor contributes to prolonged receptor desensitization: studies with A-77636.

Lin CW, Bianchi BR, Miller TR, Stashko MA, Wang SS, Curzon P, Bednarz L, Asin KE, Britton DR. Lin CW, et al. Among authors: asin ke. J Pharmacol Exp Ther. 1996 Mar;276(3):1022-9. J Pharmacol Exp Ther. 1996. PMID: 8786531

9

MK-801 differentially affects dopamine D1 and D2 receptor agonist-induced behavioral tolerance and desensitization.

Asin KE, Bednarz L, Nikkel AL. Asin KE, et al. Brain Res. 1996 Jun 24;725(1):67-74. doi: 10.1016/0006-8993(96)00348-4. Brain Res. 1996. PMID: 8828587

10

Hyperactivity and behavioral seizures in rodents following treatment with the dopamine D1 receptor agonists A-86929 and ABT-431.

Shiosaki K, Asin KE, Britton DR, Giardina WJ, Bednarz L, Mahan L, Mikusa J, Nikkel A, Wismer C. Shiosaki K, et al. Among authors: asin ke. Eur J Pharmacol. 1996 Dec 19;317(2-3):183-90. doi: 10.1016/s0014-2999(96)00718-2. Eur J Pharmacol. 1996. PMID: 8997599

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

70 results

Search Page